Shares of Resverlogix Corp. (TSE:RVX) remained flat at $C$1.31 during trading hours on Wednesday. The company had a trading volume of 16,655 shares, compared to its average volume of 40,049. Resverlogix Corp. has a 12-month low of C$1.23 and a 12-month high of C$2.41.
About Resverlogix Corp.
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.
Receive News & Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related companies with MarketBeat.com's FREE daily email newsletter.